HIV-Associated Burkitt Lymphoma Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-MIVAC with or without Rituximab in the HAART Era.pdfVIP

Hindawi Publishing Corporation Advances in Hematology Volume 2012, Article ID 735392, 9 pages doi:10.1155/2012/735392 Clinical Study HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era J. A. Rodrigo,1 L. K. Hicks,2 M. C. Cheung,3 K. W. Song,4 H. Ezzat,1 C. S. Leger,1 J. Boro,2 J. S. G. Montaner,5 M. Harris,6 and H. A. Leitch1 1 Division of Hematology, St. Paul’s Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4 2 Division of Hematology, St. Michael’s Hospital and the University of Toronto, Toronto, ON, Canada M5S 1A1 3 Division of Hematology, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, ON, Canada M5S 1A1 4 Leukemia/BMT Program of British Columbia, BC Cancer Agency, Vancouver, BC, Canada V5Z 1M9 5 British Columbia Centre for Excellence in HIV/AIDS (CFE), St. Paul’s Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4 6 AIDS Research Program, St. Paul’s Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4 Correspondence should be addressed to H. A. Leitch, hleitch@ Received 11 June 2011; Accepted 6 September 2011 Academic Editor: Jeremy S. Abramson Copyright © 2012 J. A. Rodrigo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. The outcome of HIV-associated non-Hodgkin lymphoma (NHL) has improved substantially in the highly active antiretroviral therapy (HAART) era. However, HIV-Burkitt lymphoma (BL), which accounts for up to 20% of HIV-NHL, has poor outcome with stand